Adaptive Pharmacogenomics, LLC

Pharmacogenomics. 2010 Apr;11(4):471-4

Authors: Huang RS, Dolan ME

Pharmacogenomics is emerging as an important component both in facilitating new drug development and in improving the utility of existing chemotherapeutic agents. Both candidate gene and genome-wide approaches have been used to identify genetic markers associated with chemotherapeutic response and/or toxicity.

Pharmacogenomics. 2010 Apr;11(4):573-85

Authors: Cui Y, Paules RS

Adverse drug reactions (ADRs) are an important clinical issue and a serious public health risk. Understanding the underlying mechanisms is critical for clinical diagnosis and management of different ADRs.

Pharmacogenomics. 2010 Apr;11(4):559-71

Authors: Falzoi M, Mossa A, Congeddu E, Saba L, Pani L

BACKGROUND: Pharmacogenetics is the study of genetic variations that cause alterations in drug level, drug response and adverse drug reactions. SNPs found in CYP450 genes have the greatest genetic influences on interindividual variability in drug bioavailability.

Pharmacogenomics. 2010 Apr;11(4):497-9

Authors: Alfirevic A, Pirmohamed M

Drug-induced hypersensitivity reactions represent a major concern for clinicians, patients, regulators and drug developers.

Pharmacogenomics. 2010 Apr;11(4):507-12

Authors: Lesko LJ, Zineh I

Over the past 10 years, the US FDA has become a strong pharmacogenomics advocate as part of its mission to both protect and advance public health by enabling innovations that make medicines safer to use and more effective.

Pharmacogenomics. 2010 Apr;11(4):493-6

Authors: Manolopoulos VG, Ragia G, Tavridou A

Coumarinic oral anticoagulants are life-saving drugs, but are also one of the leading causes of drug-induced major bleeding events. Moreover, there is substantial individual variation in response to coumarinic oral anticoagulants caused by several factors including variations in the CYP2C9 and VKORC1 genes.

Pharmacogenomics. 2010 Apr;11(4):481-5

Authors: Bhasker CR, Hardiman G

The past decade has seen major advances in our understanding of genomics, with the development of newer and refined technologies. Improvements in the sensitivity and precision of DNA microarrays coupled with the emergence of massively parallel sequencing techniques have redefined how we interrogate the human genome.

J Am Pharm Assoc (2003).

Pharmacogenomics. 2010 Apr;11(4):487-91

Authors: Johnson JA

Hypertension pharmacogenomics holds the promise of leading to individualized drug treatment approaches for the approximately 1 billion individuals worldwide with hypertension. Prior to 2000, the literature on hypertension pharmacogenomics was quite limited.

Pharmacogenomics. 2010 Apr;11(4):587-94

Authors: Tarr PE, Rotger M, Telenti A

HIV-infected individuals may have accelerated atherogenesis and an increased risk for premature coronary artery disease. Dyslipidemia represents a key pro-atherogenic mechanism. In HIV-infected patients, dyslipidemia is typically attributed to the adverse effects of antiretroviral therapy.